The US Food and Drug Administration (FDA) has granted Fast Track and Orphan Drug designations to TSRA-196, Tessera Therapeutics’ lead in vivo gene editing programme. TSRA-196 is being jointly developed with Regeneron for the treatment of adults with alpha-1 antitrypsin deficiency (AATD) who are homozygous for the PiZ allele (PiZZ). The therapy is designed to […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!